Showing results (11-20 of 443) with videos related to
Sort By:
Pageof 45
Seminars in Hematology|July 23, 2009
Clinical strategies to achieve an early and successful response to tyrosine kinase inhibitor therapyTimothy Hughes, Andreas HochhausHematology. American Society of Hematology. Education Program|December 10, 2021
TKI discontinuation in CML: how do we make more patients eligible? How do we increase the chances of a successful treatment-free remission?Andreas Hochhaus, Thomas ErnstSeminars in Oncology|February 1, 2012
Chronic myeloid leukemia: clinical impact of BCR-ABL1 mutations and other lesions associated with disease progressionThomas Ernst, Andreas HochhausJournal of Cancer Research and Clinical Oncology|August 15, 2013
The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patientsAndreas Hochhaus, Hagop KantarjianCurrent Opinion in Hematology|January 15, 2010
Molecular pathogenesis of tyrosine kinase resistance in chronic myeloid leukemiaPaul La Rosée, Andreas HochhausCurrent Hematologic Malignancy Reports|April 29, 2010
Resistance to imatinib in chronic myelogenous leukemia: mechanisms and clinical implicationsPaul La Rosée, Andreas HochhausBest Practice & Research. Clinical Haematology|October 11, 2020
CML - Not only BCR-ABL1 mattersJenny Rinke, Andreas Hochhaus, Thomas ErnstAnnals of Hematology|June 3, 2005
Chronic myeloid leukemia: a model for oncologyRüdiger Hehlmann, Ute Berger, Andreas HochhausDeutsche Medizinische Wochenschrift (1946)|September 11, 2018
[Chronic Myelogenous Leukemia]Andreas Hochhaus, Ekkehard Eigendorff, Thomas ErnstActa Haematologica|June 5, 2004
Molecular surveillance of chronic myeloid leukemia patients in the imatinib era - evaluation of response and resistancePeter Paschka, Kirsten Merx, Andreas HochhausPageof 45